Overview

R-BMD in Refractory or Relapsed Lymphoma, GELTAMO Clinical Trial

Status:
Completed
Trial end date:
2016-07-01
Target enrollment:
Participant gender:
Summary
Assess the combination of efficacy of the combination of rituximab, bendamustine, mitoxantrone, dexamethasone in the treatment of patients with Follicular Lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea
Treatments:
BB 1101
Bendamustine Hydrochloride
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Mitoxantrone
Rituximab